<DOC>
	<DOCNO>NCT02619162</DOCNO>
	<brief_summary>Open , multicenter phase I gradual increase dosage evaluate safety tolerability orally administer nintedanib plus letrozole orally ( 2.5 mg / day ) patient breast cancer . Nintedanib administer twice day orally 28 consecutive day ( Days 1-28 ) 4-week cycle .</brief_summary>
	<brief_title>Nintedanib+Letrozole Postmenopausal Women With Breast Cancer : Clinical Trial Safety Pharmacodynamics</brief_title>
	<detailed_description>Phase 0 / I : At level 1 include three patient . If patient suffers dose limit toxicity ( DLT ) , proceeds increase dose next level . If 2/3 patient experience DLT , close increase dose extend / investigate previous dose level 3 additional patient . If level 2 , less 1/3 minimum 6 patient experience TLD reach , phase I suspend expect another rise Level 2 . Dose level : - Level 1 : Nintedanib 150 mg twice daily + oral letrozole 2.5 mg / day orally , cycle 28 day . - Level 2 : Nintedanib 200 mg twice daily via oral + letrozole 2.5 mg / day orally , cycle 28 day . - At least first cycle administer Phase I . A total six four-week cycle administer discretion investigator .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Form sign informed consent . 2 . Women ≥ 18 year . 3 . Confirmed diagnosis invasive nonmetastatic breast cancer positive hormone receptor . The inclusion patient ductal lobular histology allow . 4 . Size great 1 cm tumor N N ≥ 1 T , include inflammatory breast cancer . 5 . Absence metastatic involvement . 6 . Postmenopausal state . Postmenopausal status define 24 month last menstrual period , previous know ovariectomy , chemical , determine FSH , LH estradiol 17B accord local laboratory value 12 month without menstruation . 7 . ECOG performance status 0 1 8 . At least one month end radiotherapy / chemotherapy . 9 . At least 6 week since major surgery . 10 . Patients currently treat letrozole le 6 month . 11 . Primary surgery breast cancer already do . The elderly woman advance local regional tumor hormone treatment administer monotherapy , regardless intent surgery candidate . 12 . LVEF &gt; 50 % 13 . Renal function , liver adequate hematologic , define follow analytical result within 14 day prior randomization registration : Absolute granulocyte count &gt; 1.5 x 109 / L Absolute platelet count &gt; 100 x 109 / L Hemoglobin &gt; 10 g / dl Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance &gt; 50 ml / min Serum bilirubin &lt; 1.25 ULN AST / ALT ≤ 1.5 time LS 14 . Toxicities associate chemotherapy recovery lesser extent 2 tolerable . 15 . Life expectancy &gt; 6 month . 1 . HER2 overexpression define positive immunohistochemistry HER2positive 2+ 3+ FISH / CISH . 2 . Absence tumor tissue file . 3 . T1 N0 stage patient exclude . 4 . Malignancy concomitant active , diagnosis another malignancy within last five year , apart nonmelanoma ductal / tubular breast carcinoma skin cancer ( receive hormone treatment ) situ cervical cancer , carcinoma colon situ treat properly , well diagnosis tumor less five year inclusion unsigned progression today . 5 . Women childbearing potential . 6 . Pretreatment nintedanib . Use investigational drug administration adjuvant neoadjuvant treatment exclusion criterion long toxicity recovers . 7 . Medical Condition concomitant serious , like eg myocardial infarction within 6 uncontrolled prior inclusion study month , congestive heart failure , unstable angina , cardiomyopathy active , unstable ventricular arrhythmia , hypertension ( accord criterion NYHA ) , psychotic disorder uncontrolled severe active infection , active peptic ulcer disease , psychiatric disease , HIV infection , active hepatitis , COPD medical condition might aggravate treatment limit compliance . 8 . Inability make oral , history malabsorption syndrome medication . 9 . Failure comply study followup procedure . 10 . Anticoagulant therapy ( except lowdose heparin heparin wash need maintain permanent intravenous device ) antiplatelet therapy ( except lowdose therapy aspirin , less 325 mg daily ) . 11 . History thromboembolic hemorrhagic episode clinically relevant past 6 month hereditary predisposition bleed thrombosis . 12 . Contraindication hormonal blockade absence hormoneblocking prescription doctor reason . Metastatic breast cancer nonsurgical ( include inflammatory ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>breast cancer non metastatic</keyword>
	<keyword>adjuvant letrozole</keyword>
	<keyword>Nintedanib BIFF1120</keyword>
</DOC>